Ozone Partially Prevents Diabetic Neuropathy in Rats

 

 Buy Article Permissions and Reprints

Abstract

Neuropathy is one of the most common complications of diabetes mellitus. Although the beneficial effects of good blood glucose control on diabetic neuropathy are known, this control cannot completely prevent the occurrence and progression of diabetic neuropathy. The aim of this study was to investigate whether ozone prevents diabetic neuropathy. 36 adult female Sprague-Dawley rats were randomly divided into 6 groups (n=6): control (C), ozone (O), diabetic (D), ozone-treated diabetic (DO), insulin-treated diabetic (DI), and ozone- and insulin-treated diabetic (DOI). Diabetes was induced by a single injection of streptozotocin (60 mg/kg, intraperitoneal [i.p.]), after which insulin was administered (3 IU, i.p.) to the DI and DOI groups for 28 days, and 1.1 mg/kg (50 µg/ml) ozone was given to the O, DO, and DOI groups for 15 days. 4 weeks after the induction of diabetes, the nerve conduction velocity (NCV), amplitude of the compound action potential (CAP), total oxidant status (TOS), and total antioxidant status (TAS) were measured, and the oxidative stress index (OSI) was calculated. The NCV, amplitude of CAP, and TAS of the DI and DOI groups were higher than those of the D group; the amplitudes of CAP and TAS of the DO group were higher than those of the D group; and the TOS and OSI of the DO, DI, and DOI groups were lower than those of the D group. These findings indicate that ozone partially prevents diabetic neuropathy in rats. It appears that the preventive effects of ozone are mediated through oxidant/antioxidant mechanisms.

• References

• 1 International Diabetes Federation . The global burden, IDF Diabetes Atlas. 6^th ed Brussels, Belgium: International Diabetes Federation; 2013: 29-48 http://www.idf.org/diabetesatlas
  Google Scholar
• 2 Tesfaye S, Boulton AJ, Dyck PJ et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293
  CrossrefPubMedGoogle Scholar
• 3 Hyllienmark L, Alstrand N, Jonsson B et al. Early electrophysiological abnormalities and clinical neuropathy: a prospective study in patients with type 1 diabetes. Diabetes Care 2013; 36: 3187-3194
  CrossrefPubMedGoogle Scholar
• 4 Battino R, Rettich TR, Tominaga T. The solubility of oxygen and ozone in liquids. J Phys Chem Ref Data 1983; 12: 163-178
  CrossrefPubMedGoogle Scholar
• 5 León OS, Menéndez S, Merino N et al. Ozone oxidative preconditioning: a protection against cellular damage by free radicals. Mediators Inflamm 1998; 7: 289-294
  CrossrefPubMedGoogle Scholar
• 6 Peralta C, León OS, Xaus C et al. Protective effect of ozone treatment on the injury associated with hepatic ischemia-reperfusion: antioxidant-prooxidant balance. Free Radic Res 1999; 31: 191-196
  CrossrefPubMedGoogle Scholar
• 7 Hernández F, Menéndez S, Wong R. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic Biol Med 1995; 19: 115-119
  CrossrefPubMedGoogle Scholar
• 8 Martínez-Sánchez G, Al-Dalain SM, Menéndez S et al. Therapeutic efficacy of ozone in patients with diabetic foot. Eur J Pharmacol 2005; 523: 151-161
  CrossrefPubMedGoogle Scholar
• 9 Yagihashi S. Nerve structural defects in diabetic neuropathy: do animals exhibit similar changes?. Neurosci Res Commun 1997; 21: 25-32
  CrossrefPubMedGoogle Scholar
• 10 Biessels GJ, Cristino NA, Rutten GJ et al. Neurophysiological changes in the central and peripheral nervous system of streptozotocin-diabetic rats. Brain 1999; 122: 757-768
  CrossrefPubMedGoogle Scholar
• 11 Leonelli E, Bianchi R, Cavaletti G et al. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. Neuroscience 2007; 144: 1293-1304
  CrossrefPubMedGoogle Scholar
• 12 DCCT Research Group . The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-568
  CrossrefPubMedGoogle Scholar
• 13 Apfel SC, Kessler JA, Adornato BT et al. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998; 51: 695-702
  CrossrefPubMedGoogle Scholar
• 14 Veiga S, Leonelli E, Beelke M et al. Neuroactive steroids prevent peripheral myelin alterations induced by diabetes. Neurosci Lett 2006; 402: 150-153
  CrossrefPubMedGoogle Scholar
• 15 Ido Y, McHowat J, Chang KC et al. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes 1994; 43: 1469-1477
  CrossrefPubMedGoogle Scholar
• 16 Pitel S, Raccah D, Gerbi A et al. At low doses, a gamma-linolenic acid-lipoic acid conjugate is more effective than docosahexaenoic acid-enriched phospholipids in preventing neuropathy in diabetic rats. J Nutr 2007; 137: 368-372
  PubMedGoogle Scholar
• 17 Ziegler D, Low PA, Litchy WJ et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011; 34: 2054-2060
  CrossrefPubMedGoogle Scholar
• 18 Pesaresi M, Giatti S, Cavaletti G et al. Sex-dimorphic effects of dehydroepiandrosterone in diabetic neuropathy. Neuroscience 2011; 199: 401-409
  CrossrefPubMedGoogle Scholar
• 19 Roglio I, Bianchi R, Giatti S et al. Testosterone derivatives are neuroprotective agents in experimental diabetic neuropathy. Cell Mol Life Sci 2007; 64: 1158-1168
  CrossrefPubMedGoogle Scholar
• 20 Morsy MD, Hassan WN, Zalat SI. Improvement of renal oxidative stress markers after ozone administration in diabetic nephropathy in rats. Diabeteol Metabol Syndr 2010; 2: 29-35
  PubMedGoogle Scholar
• 21 Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103-1111
  CrossrefPubMedGoogle Scholar
• 22 Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004; 37: 112-119
  CrossrefPubMedGoogle Scholar
• 23 Singhal A, Cheng C, Sun H et al. Near nerve local insulin prevents conduction slowing in experimental diabetes. Brain Res 1997; 763: 209-214
  CrossrefPubMedGoogle Scholar
• 24 Hasegawa O, Matsumoto S, Iino M et al. Interrelationship among nerve conduction velocity, amplitudes of compound muscle and compound nerve action potentials in diabetic neuropathy. No To Shinkei 1999; 51: 863-866
  PubMedGoogle Scholar
• 25 Lin Q, Chen H, Lu C et al. Effects of ozone on sciatic nerve in rat. Interv Neuroradiol 2011; 17: 281-285
  PubMedGoogle Scholar
• 26 Vincent AM, Russell JW, Low P et al. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25: 612-628
  CrossrefPubMedGoogle Scholar
• 27 Ceretta LB, Réus GZ, Abelaira HM et al. Increased oxidative stress and imbalance in antioxidant enzymes in the brains of alloxan-induced diabetic rats. Exp Diabetes Res 2012; 2012: 1-8
  PubMedGoogle Scholar
• 28 Bocci V, Borrelli E, Travagli V et al. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev 2009; 29: 646-682
  CrossrefPubMedGoogle Scholar
• 29 Martín-Gallán P, Carrascosa A, Gussinyé M et al. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34: 1563-1574
  CrossrefPubMedGoogle Scholar
• 30 Serban MG, Negru T. Lipoproteins, lipidic peroxidation and total antioxidant capacity in serum of aged subjects suffering from hyperglycemia. Rom J Intern Med 1998; 36: 65-70
  PubMedGoogle Scholar
• 31 Al-Dalain SM, Martínez G, Candelario-Jalil E et al. Ozone treatment reduces markers of oxidative and endothelial damage in an experimental diabetes model in rats. Pharmacol Res 2001; 44: 391-396
  CrossrefPubMedGoogle Scholar
• 32 Candelario-Jalil E, Mohammed-Al-Dalain S, Fernández OS et al. Oxidative preconditioning affords protection against carbon tetrachloride-induced glycogen depletion and oxidative stress in rats. J Appl Toxicol 2001; 21: 297-301
  CrossrefPubMedGoogle Scholar
• 33 Ceriello A, Mercuri F, Quagliano L et al. Detection of nitrotynosive in the diabetic plasma: evidence of oxidative stress. Diabetología 2001; 44: 834-838
  CrossrefPubMedGoogle Scholar
• 34 Fesken EJ, Vintanen SM. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the seven countries study. Diabetes Care 1995; 18: 1104-1112
  CrossrefPubMedGoogle Scholar